Surgical Science Sweden Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Tom Englund
Algemeen directeur
n/a
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | less than a year |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 3.8yrs |
| Gemiddelde ambtstermijn bestuur | 3.5yrs |
Recente managementupdates
Recent updates
The Price Is Right For Surgical Science Sweden AB (publ) (STO:SUS)
Nov 12
Surgical Science Sweden AB (publ) Just Missed EPS By 22%: Here's What Analysts Think Will Happen Next
Aug 25Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Is There Now An Opportunity In Surgical Science Sweden AB (publ) (STO:SUS)?
Nov 29Should You Be Adding Surgical Science Sweden (STO:SUS) To Your Watchlist Today?
Oct 07Is Surgical Science Sweden AB (publ) (STO:SUS) Trading At A 39% Discount?
Aug 17With EPS Growth And More, Surgical Science Sweden (STO:SUS) Makes An Interesting Case
Jun 20A Look At The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
May 17Surgical Science Sweden AB (publ) (STO:SUS) Shares Could Be 49% Below Their Intrinsic Value Estimate
Dec 27Is Now The Time To Put Surgical Science Sweden (STO:SUS) On Your Watchlist?
Dec 06Is Now The Time To Look At Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Sep 08We Ran A Stock Scan For Earnings Growth And Surgical Science Sweden (STO:SUS) Passed With Ease
Aug 23Surgical Science Sweden AB (publ) (STO:SUS) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
May 26Here's Why We Think Surgical Science Sweden (STO:SUS) Is Well Worth Watching
Apr 29An Intrinsic Calculation For Surgical Science Sweden AB (publ) (STO:SUS) Suggests It's 44% Undervalued
Feb 20Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jan 11Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Dec 15Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Sep 16Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jul 05Calculating The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Jun 08Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Mar 23Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Mar 02Is Surgical Science Sweden AB (publ)'s (STO:SUS) Shareholder Ownership Skewed Towards Insiders?
Feb 09
Surgical Science Sweden AB (publ)'s (STO:SUS) Stock Is Going Strong: Have Financials A Role To Play?
Jan 01What Does Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Indicate?
Dec 14Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Nov 26CEO
Tom Englund (48 yo)
less than a year
Tenure
Mr. Tom Englund is Chief Executive Officer of Surgical Science Sweden AB (publ) from October 1, 2024. Mr. Englund served as Division Chief Executive Officer of Tobii Pro and Deputy Chief Executive Officer...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Advisor & Director | less than a year | SEK 5.83m | 0.67% SEK 50.1m | |
| Chief Executive Officer | less than a year | geen gegevens | geen gegevens | |
| Co-Founder & CTO | 5.8yrs | geen gegevens | 0.059% SEK 4.4m | |
| Chief Financial Officer | 6.8yrs | geen gegevens | 0.047% SEK 3.5m | |
| Chief Operating Officer | 3.8yrs | geen gegevens | 0.036% SEK 2.7m | |
| Head of Global Sales | 3.8yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Products & Marketing | 3yrs | geen gegevens | 0.036% SEK 2.7m | |
| Head of Development | 5yrs | geen gegevens | geen gegevens | |
| Chief Innovation Officer | 3.8yrs | geen gegevens | geen gegevens | |
| President of Research & Development | 2.8yrs | geen gegevens | 0.042% SEK 3.2m | |
| Executive Vice President of International Sales & Educational Products | no data | geen gegevens | 0.010% SEK 753.2k | |
| Executive Vice President of Industry & OEM | 2.5yrs | geen gegevens | geen gegevens |
3.8yrs
Gemiddelde duur
54.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SUS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Advisor & Director | less than a year | SEK 5.83m | 0.67% SEK 50.1m | |
| Chairman of the Board | 19.8yrs | geen gegevens | 11.74% SEK 876.7m | |
| Director | 19.8yrs | geen gegevens | 13.99% SEK 1.0b | |
| Independent Director | 7.8yrs | geen gegevens | 0.0020% SEK 146.3k | |
| Independent Director | 1.5yrs | geen gegevens | 0.00069% SEK 51.5k | |
| Independent Director | 3.5yrs | geen gegevens | 0.0026% SEK 190.4k | |
| Independent Director | 3.5yrs | geen gegevens | 0.0020% SEK 146.3k |
3.5yrs
Gemiddelde duur
52yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SUS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).